Predictive factors of lymph node metastasis and pattern of repartition in patients with epithelial ovarian cancer

2021 ◽  
Author(s):  
David Atallah ◽  
Wissam Arab ◽  
Bruno Dagher ◽  
Nour Khalil ◽  
Elsa El Rawadi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Lymph Node ◽  
Epithelial Ovarian Cancer ◽  
Care Center ◽  
Clinical Stage ◽  
Univariate Analysis ◽  
Tertiary Care ◽  
Peritoneal Cytology ◽  
Advanced Clinical Stage ◽  
Positive Peritoneal Cytology

Aim: To determine the rate, repartition and risk factors of lymph node (LN) metastasis in patients with epithelial ovarian cancer. Methods: We reviewed retrospectively the pathological and clinical data of 184 patients with epithelial ovarian cancer at a tertiary care center in Beirut, Lebanon. Results: 88% of patients received a pelvic and para-aortic lymphadenectomy. 70% of patients presented LN metastases at both pelvic and para-aortic levels, while isolated pelvic or para-aortic LN metastases were seen in 16 and 14% of cases, respectively. In a univariate analysis, the rate of positive LNs was higher in patients with serous histology (65 vs 33%; p < 0.001), high-grade tumors (68 vs 26%; p < 0.001), bilateral adnexal involvement (74 vs 27%; p < 0.001), advanced clinical stage (p < 0.001), interval debulking surgery (63.2 vs 36.8%; p = 0.003) and positive peritoneal cytology (79 vs 26%; p < 0.001). In a multivariate analysis, the rate of LN involvement was significantly higher in patients with higher grade, advanced clinical stage and positive peritoneal cytology. Conclusion: Serous histology, grade 3 tumors, positive peritoneal cytology, advanced clinical stage, interval surgery and bilateral adnexal involvement can predict LN metastasis in patients with epithelial ovarian cancer.

Contralateral Pelvic and Aortic Lymph Node Metastasis in Clinical Stage I Epithelial Ovarian Cancer

1999 ◽  
Vol 74 (1) ◽  
pp. 128-129 ◽  
Author(s):  
Andrew J. Walter ◽  
Javier F. Magrina
Keyword(s):  
Ovarian Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Epithelial Ovarian Cancer ◽  
Clinical Stage ◽  
Stage I ◽  
Node Metastasis ◽  
Aortic Lymph Node

DEMOGRAPHIC PROFILE AND OUTCOMES OF ADVANCED EPITHELIAL OVARIAN CANCER

2021 ◽  
Vol 5 (5) ◽  
Author(s):  
Ankit Agarwal ◽  
Arun Pandey ◽  
Giriraj Prajapati
Keyword(s):  
Ovarian Cancer ◽  
Prognostic Factors ◽  
Epithelial Ovarian Cancer ◽  
Clinical Stage ◽  
Tertiary Care ◽  
Survival Rates ◽  
Disease Free Survival ◽  
Abdominal Distension ◽  
Care Hospital ◽  
Loss Of Appetite

Background: To study the epidemiological features and outcome of epithelial ovarian cancer patients treated at a tertiary care hospital. Methods: We conducted a retrospective study at our institute to identify patients diagnosed with epithelial Ovarian Carcinoma (EOC) from 2013 to 2018. We studied the epidemiological profile and the outcome of the treatment in terms of response rates, Disease-free survival, and overall survival rates. Results: A total of 238 patients were diagnosed with EOC over a period of 7 years. Out of 238 patients, complete pretreatment data was available for 197 patients. The median age at diagnosis was 59 years (range: 34–85 years). Totally 39 patients (16.38%) were younger than 45 years of age. The common presenting features were abdominal distension (82%), dysuria (43%), abdominal pain (40%), loss of appetite (36%), constipation (32%), shortness of breath (15%). serum CA125 levels were elevated in 73% cases at presentation Conclusion: In conclusion, it is of extreme importance to identify the prognostic factors in patients with ovarian cancer to enable us to choose the most appropriate treatment strategy and to identify the risk of progression and death at follow-up. In our study, the patient age and FIGO clinical stage were the only independent prognostic factors reported. Keywords: FIGO, Ovarian, Germ cell

scholarly journals 71 Neoadjuvant chemotherapy in epithelial ovarian cancer: a case-control study in a Lebanese tertiary care center

2020 ◽  
Author(s):  
D Atallah ◽  
M Moubarak ◽  
B Dagher ◽  
N Khalil ◽  
N El Kassis ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Epithelial Ovarian Cancer ◽  
Case Control Study ◽  
Care Center ◽  
Tertiary Care ◽  
Case Control ◽  
Tertiary Care Center ◽  
Control Study

scholarly journals Role of pelvic and para-aortic lymphadenectomy in epithelial ovarian cancers

2019 ◽  
Vol 9 (1) ◽  
pp. 328
Author(s):  
Pankush Gupta ◽  
Sunesh Kumar ◽  
Seema Singhal ◽  
Jyoti Meena ◽  
Sandeep Mathur ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Lymph Node ◽  
Epithelial Ovarian Cancer ◽  
Operating Time ◽  
Lymph Node Involvement ◽  
Peritoneal Cytology ◽  
Nodal Involvement ◽  
Surgical Morbidity ◽  
Ovarian Cancers ◽  
Node Involvement

Background: Lymphadenectomy in epithelial ovarian cancers has remained a controversial subject. Lack of robust evidence on survival benefits and surgical morbidity associated questions its role in the era of adjuvant chemotherapy. The present study assessed pelvic and para-aortic lymph node removal in epithelial ovarian cancer in Indian women and tried to find clinicopathological correlation of nodal involvement and postoperative implications of lymphadenectomy.Methods: Thirty patients with diagnosis of epithelial ovarian cancer posted for primary debulking surgery were recruited and underwent staging laparotomy along with pelvic and para-aortic lymphadenectomy. Nodal involvement was confirmed on histopathology and various parameters which could predict nodal metastasis were assessed. Patients were followed up for 12 months post-surgery.Results: Nodal yield was ten for pelvic and four for paraaortic nodes. Pelvic node involvement was seen in 26.6% (8/30) of the patients and para-aortic in 15% (3/20) of the patients. Serous histology, higher grade, stage 3 and above, positive peritoneal cytology, omental involvement showed a higher lymph node involvement though not statistically significant. Para-aortic lymphadenectomy was associated with increased operating time, blood loss and longer hospital stay.Conclusions: Lymphadenectomy increases morbidity and decision should be based on predictors of nodal involvement.

scholarly journals Lymph node metastasis in grossly apparent clinical stage Ia epithelial ovarian cancer: Hacettepe experience and review of literature

2010 ◽  
Vol 8 (1) ◽  
Author(s):  
Guldeniz Aksan Desteli ◽  
Murat Gultekin ◽  
Alp Usubutun ◽  
Kunter Yuce ◽  
Ali Ayhan
Keyword(s):  
Ovarian Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Epithelial Ovarian Cancer ◽  
Clinical Stage ◽  
Review Of Literature ◽  
Node Metastasis ◽  
Clinical Stage Ia ◽  
Stage Ia

Evaluation of Factors Affecting Lymph Node Metastasis in Clinical Stage I-II Epithelial Ovarian Cancer

2018 ◽  
Vol 41 (7-8) ◽  
pp. 444-448
Author(s):  
Baki Erdem ◽  
Ilkbal T. Yüksel ◽  
Nuri Peker ◽  
Suat C. Ulukent ◽  
Osman Aşıcıoğlu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Epithelial Ovarian Cancer ◽  
Clinical Stage ◽  
Stage I ◽  
Factors Affecting ◽  
Node Metastasis

scholarly journals A prospective study evaluating preoperative (clinical, imaging) and intraoperative predictors of suboptimal debulking in advanced epithelial ovarian cancer

2016 ◽  
Author(s):  
Anupama Rajanbabu ◽  
Kiran Bagul ◽  
Keyword(s):  
Ovarian Cancer ◽  
Small Bowel ◽  
Ct Scan ◽  
Epithelial Ovarian Cancer ◽  
Survival Benefit ◽  
Demographic Data ◽  
Univariate Analysis ◽  
Imaging Results ◽  
Advanced Epithelial Ovarian Cancer ◽  
Optimal Debulking

Introduction: In advanced epithelial ovarian cancer, there is a survival benefit for patients who achieve optimalcytoreduction. Suboptimallycytoreduced patients are at risk of the increased morbidity of a surgery without associated survival benefit. Predicting which patients can undergo optimal cytoreduction represents a critical decision-making point. Present study analyses the predictors, pre operative (clinical and radiologic) and intraoperative of suboptimal debulking. Methods: This was a prospective observational study conducted at Amrita Institute of Medical Sciences from March 2013 to May 2015. All the patients with clinically (physical examination, laboratory and imaging results) diagnosed Stage IIIc epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (PPC) who were planed for primary debulking surgery were included. The demographic data and details of tumor markers, radiological investigations including CT scan, intra operative findings and histopathologic details were collected. Statistical analysis was done using SPSS v20.0. Results: 36 patients fit the inclusion criteria. Gross ascites wasthe clinical parameter found to be associated with suboptimal debulking. CT scan had low sensitivity (35-53%) in diagnosing small bowel mesenteric and porta hepatis disease and high sensitivity in diagnosing diffuse peritoneal thickening, omental disease, diaphragmatic and nodal disease. On univariate analysis diffuse peritoneal thickening and small bowel serosa and mesenteric disease were significantly consistent with sub optimal debulking. Conclusion: Finding out disease at the sites which are associated with suboptimal debulking (diffuse peritoneal thickening, smallbowel mesenteric and serosal disease) pre operatively or at the beginning of surgery can predict optimal debulking and can help avoid un necessary surgery.

scholarly journals Clinical Impact of Lymphadenectomy after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Review of Available Data

2021 ◽  
Vol 10 (2) ◽  
pp. 334
Author(s):  
Stephanie Seidler ◽  
Meriem Koual ◽  
Guillaume Achen ◽  
Enrica Bentivegna ◽  
Laure Fournier ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Lymph Node ◽  
Neoadjuvant Chemotherapy ◽  
Epithelial Ovarian Cancer ◽  
Lymph Node Dissection ◽  
Prospective Trial ◽  
Node Dissection ◽  
Advanced Epithelial Ovarian Cancer ◽  
The Impact ◽  
Systematic Lymph Node Dissection

Recent robust data allow for omitting lymph node dissection for patients with advanced epithelial ovarian cancer (EOC) and without any suspicion of lymph node metastases, without compromising recurrence-free survival (RFS), nor overall survival (OS), in the setting of primary surgical treatment. Evidence supporting the same postulate for patients undergoing complete cytoreductive surgery after neoadjuvant chemotherapy (NACT) is lacking. Throughout a systematic literature review, the aim of our study was to evaluate the impact of lymph node dissection in patients undergoing surgery for advanced-stage EOC after NACT. A total of 1094 patients, included in six retrospective series, underwent either systematic, selective or no lymph node dissection. Only one study reveals a positive effect of lymphadenectomy on OS, and two on RFS. The four remaining series fail to demonstrate any beneficial effect on survival, neither for RFS nor OS. All of them highlight the higher peri- and post-operative complication rate associated with systematic lymph node dissection. Despite heterogeneity in the design of the studies included, there seems to be a trend showing no improvement on OS for systematic lymph node dissection in node negative patients. A well-conducted prospective trial is mandatory to evaluate this matter.

Sign in / Sign up

Export Citation Format

Share Document